



Together, let's work towards providing access to another chickenpox vaccine for all our little ones



Join our clinical research study that is aiming to offer a potential new vaccine option to help protect toddlers from chickenpox

Chickenpox (varicella) is a very contagious infection that can cause serious complications in children. Access to chickenpox vaccines is important because vaccination is the only way to help protect children from chickenpox.

The Lullaby Study is looking at an investigational vaccine (a "study vaccine") to help prevent chickenpox in children. The study will look at how safe the study vaccine is and whether it works in children. To achieve this, the study vaccine will be compared with an approved chickenpox vaccine (a "reference vaccine") that is already available for use in the USA.

Your child may be able to take part if they:

- are 12–15 months of age
- are in good health
- have received their first 3 doses (primary series) of a pneumococcal conjugate vaccine (a vaccine that protects against the *Streptococcus pneumoniae* bacteria, which cause ear, lung, and other infections).

The study will last about 6 months and will include 3 study visits and 2 phone contacts for safety follow-up.

Your child will receive 1 dose of either the study vaccine or the reference vaccine. They will also receive 1 dose of the following approved vaccines that are part of the recommended childhood routine vaccination schedule in the USA to help protect against:

- Measles, mumps, and rubella
- Hepatitis A
- Streptococcus pneumoniae bacteria.

The Lullaby Study has been approved by an Institutional Review Board (IRB), which protects the rights, safety, and well-being of study participants.

Want to know more?

To learn more, please contact us:

Abdullah Warsama awarsama@msm.edu (440) 834-2576 Vaccine Trials Unit vturesearch@msm.edu (888)788-0644

To learn more about this study, please visit **qrco.de/Lullaby** or scan this QR code using a smartphone camera.









